Response rate and survival in myeloma patients receiving prednisone alone

摘要: Thirty-two evaluable good risk patients with multiple myeloma received a 70-day tapering course of prednisone beginning at dose 1.2 mg/kg/day. Forty-four percent the demonstrated objective evidence response to this treatment. Although median time disease progression for prednisone-treated group was shorter than randomized receive alkylating agents or who were treated agent alone, results from trial indicate that prednisone, by itself, may produce responses. Caution must be used interpreting trials new in when such treatments are combined corticosteroid administration.